insights_auto
Why is ADAPY down 2,63%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,037 $
arrow_downward
-2,63%(-0,00100) 1D
2 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
0,02 $
High
0,04 $
Low
0,02 $
Mkt. cap
9,32 млн
Avg. vol.
208,88 м.
Volume
64,75 мың
52-wk high
0,28 $
52-wk low
0,00 $
Beta
0,75
Shares outstanding
265,05 млн
No. of employees
272
Open
0,02 $
High
0,04 $
Low
0,02 $
Mkt. cap
9,32 млн
Avg. vol.
208,88 м.
Volume
64,75 мың
52-wk high
0,28 $
52-wk low
0,00 $
Beta
0,75
Shares outstanding
265,05 млн
No. of employees
272
News stories
From web sources and news partners
MarketBeat
·
10 минут бұрын
National Energy Services Reunited (NASDAQ:NESR) Cut to Hold at Zacks Research
Business Insider
·
46 минут бұрын
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
FXLeaders
·
39 минут бұрын
Ripple bullish forecast: Evernorth’s 473M XRP Token Nasdaq Debut Could Trigger a Supply Crunch
WSJ
·
13 сағат бұрын
Nasdaq Leads Stocks Higher as Hiring Softens
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR